成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Protein Tyrosine Kinase/RTK
  3. IGF-1R
  4. Robatumumab

Robatumumab  (Synonyms: 羅妥木單抗; Sch 717454; 19D12)

目錄號: HY-P99218 純度: 99.90%
COA 技術支持

Robatumumab (Sch 717454) 是一種 anti-human IGF-1R (胰島素樣生長因子 1 受體) 抗體。Robatumumab 具有抗腫瘤活性和抗癌細胞增殖活性。Robatumumab 可用于骨肉瘤和尤文肉瘤的研究。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

我們將采用定制合成服務的方式為您快速提供所需產(chǎn)品和技術服務

CAS No. : 934235-44-6

1.  客戶無需承擔相應的運輸費用。

2.  同一機構（單位）同一產(chǎn)品試用裝僅限申領一次，同一機構（單位）一年內(nèi)

     可免費申領三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
1 mg ￥2900
In-stock
5 mg ￥7250
In-stock
10 mg   詢價  
50 mg   詢價  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research[1][2].

同型

Human IgG1(E356D/M358L) kappa
推薦同型對照抗體
種屬

Human
體外研究
(In Vitro)

Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[2]

Cell Line: SK-N-FI cells
Concentration: 0.02-80 nM
Incubation Time: 0.5 or 4 hours
Result: Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation.
體內(nèi)研究
(In Vivo)

Robatumumab (intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 d) inhibits the SK-N-FI tumor growth in xenograft model[2].
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nude mice inoculated with SK-N-FI tumor cells[2]
Dosage: 0.04 or 0.1 mg/mouse
Administration: Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
Result: Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage: 0.02, 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
Result: Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
Animal Model: Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2]
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
Result: Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
Animal Model: Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2]
Dosage: 0.1 or 0.5 mg/mouse
Administration: Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
Result: Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
Animal Model: Nude mice inoculated with SJSA-1 osteosarcoma[2]
Dosage: 0.5 mg/mouse
Administration: Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
Result: Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
Clinical Trial
CAS 號
性狀

液體

顏色

Colorless to light yellow

中文名稱

羅妥木單抗
運輸條件

Shipping with dry ice.
儲存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
純度 & 產(chǎn)品資料
參考文獻

  • 摩爾計算器

  • 稀釋計算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   體積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start) × 體積 (start) = 濃度 (final) × 體積 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機構名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Robatumumab
目錄號：
HY-P99218
需求量：